Monthly Archives: June 2020

NICE ink developed by Texas A&M researchers can be used to 3D print customizable craniofacial implants.

Courtesy of Akhilesh Gaharwar

Subtle variations in the architecture of the 22 bones of the skull give each one of us a unique facial profile. So repairing the shape of skull defects, in the event of a fracture or a congenital deformity, calls for a technique that can be tailored to an individuals face or head structure.

In a new study, researchers at Texas A&M University have combined 3D printing, biomaterial engineering and stem cell biology to create superior, personalized bone grafts. When implanted at the site of repair, the researchers said these grafts will not only facilitate bone cells to regrow vigorously, but also serve as a sturdy platform for bone regeneration in a desired, custom shape.

Materials used for craniofacial bone implants are either biologically inactive and extremely hard, like titanium, or biologically active and too soft, like biopolymers, said Roland Kaunas, associate professor in the Department of Biomedical Engineering. In our study, we have developed a synthetic polymer that is both bioactive and mechanically strong. These materials are also 3D printable, allowing custom-shaped craniofacial implants to be made that are both aesthetically pleasing and functional.

A detailed report on the findings was published online in the journalAdvanced Healthcare Materialsin March.

Each year, about 200,000 injuries occur to bones of the jaw, face and head. For repair, physicians often hold these broken bones in place using titanium plates and screws so that surrounding bone cells can grow and form a cover around the metal implant. Despite its overall success in aiding bone repair, one of the major drawbacks of titanium is that it does not always integrate into bone tissue, which can then cause the implant to fail, requiring another surgery in advanced cases.

Thus, biocompatible polymers, particularly a type called hydrogels, offer a preferable alternative to metal implants. These squishy materials can be loaded with bone stems cells and then 3D printed to any desired shape. Also, unlike titanium plates, the body can degrade hydrogels over time. However, hydrogels also have a known weakness.

Although the pliability of hydrogel-based materials makes them good inks for 3D bioprinting, their softness compromises the mechanical integrity of the implant and the accuracy of printed parts, said Akhilesh Gaharwar, associate professor in the Department of Biomedical Engineering.

To increase the stiffness of the hydrogel, the researchers developed a nanoengineered ionic-covalent entanglement or NICE recipe containing just three main ingredients: an extract from seaweed called kappa carrageenan, gelatin and nanosilicate particles that both stimulate bone growth and mechanically reinforce the NICE hydrogel.

First, they uniformly mixed the gelatin and kappa carrageenan at microscopic scales and then added the nanosilicates. Gaharwar said the chemical bonds between these three items created a much stiffer hydrogel for 3D bioprinting with an almost eight-fold increase in strength compared to individual components of NICE bioink.

Next, they added adult stem cells to 3D parts printed with NICE ink and then chemically induced the stem cells to convert into bone cells. Within a couple of weeks, the researchers found that the cells had grown in numbers, producing high levels of bone-associated proteins, minerals and other molecules. In aggregate, these cell secretions formed a scaffold, known as an extracellular matrix, with a unique composition of biological materials needed for the growth and survival of developing bone cells.

When the scaffolds are fully developed, the researchers noted that the bone cells could be removed from the scaffold and the hydrogel-based implant can then be inserted into the site of skull injury where the surrounding, healthy bones initiate healing.Over time, the 3D printed scaffolds biodegrade, leaving behind a healed bone in the right shape.

The idea is to have the bodys own bone repair machinery participate in the repair process, Kaunas said. Our biomaterial is enriched with this regenerative extracellular matrix, providing a fertile environment to naturally trigger bone and tissue restoration.

The researchers said that the 3D-printed scaffolds provide a strong structural framework that facilitates the attachment and growth of healthy bone cells. Also, they found that developing bone cells penetrate through the synthetic material, thereby increasing the functionality of the implant.

Although our current work is focused on repairing skull bones, in the near future, we would like to expand this technology for not just craniomaxillofacial defects but also bone regeneration in cases of spinal fusions and other injuries, Kaunas said.

Other contributors to this study include Candice Sears, Eli Mondragon, Zachary Richards, Nick Sears and David Chimene from the Texas A&M Department of Biomedical Engineering; and Eoin McNeill and Carl A. Gregory from the Texas A&M Health Science Center.

This research is funded by the National Institutes of Health and the National Science Foundation.

See the rest here:
Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts - Texas A&M University Today

A team of researchers has generated a developmental map of a key sound-sensing structure in the mouse inner ear. Scientists at the National Institute on Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health, and their collaborators analyzed data from 30,000 cells from mouse cochlea, the snail-shaped structure of the inner ear. The results provide insights into the genetic programs that drive the formation of cells important for detecting sounds. The study also sheds light specifically on the underlying cause of hearing loss linked to Ehlers-Danlos syndrome and Loeys-Dietz syndrome.

The study data is shared on a unique platform open to any researcher, creating an unprecedented resource that could catalyze future research on hearing loss. Led by Matthew W. Kelley, Ph.D., chief of the Section on Developmental Neuroscience at the NIDCD, the study appeared online in Nature Communications(link is external). The research team includes investigators at the University of Maryland School of Medicine, Baltimore; Decibel Therapeutics, Boston; and Kings College London.

Unlike many other types of cells in the body, the sensory cells that enable us to hear do not have the capacity to regenerate when they become damaged or diseased, said NIDCD Director Debara L. Tucci, M.D., who is also an otolaryngology-head and neck surgeon. By clarifying our understanding of how these cells are formed in the developing inner ear, this work is an important asset for scientists working on stem cell-based therapeutics that may treat or reverse some forms of inner ear hearing loss.

In mammals, the primary transducers of sound are hair cells, which are spread across a thin ribbon of tissue (the organ of Corti) that runs the length of the coiled cochlea. There are two kinds of hair cells, inner hair cells and outer hair cells, and they are structurally and functionally sustained by several types of supporting cells. During development, a pool of nearly identical progenitor cells gives rise to these different cell types, but the factors that guide the transformation of progenitors into hair cells are not fully understood.

To learn more about how the cochlea forms, Kelleys team took advantage of a method called single-cell RNA sequencing. This powerful technique enables researchers to analyze the gene activity patterns of single cells. Scientists can learn a lot about a cell from its pattern of active genes because genes encode proteins, which define a cells function. Cells gene activity patterns change during development or in response to the environment.

There are only a few thousand hair cells in the cochlea, and they are arrayed close together in a complex mosaic, an arrangement that makes the cells hard to isolate and characterize, said Kelley. Single-cell RNA sequencing has provided us with a valuable tool to track individual cells behaviors as they take their places in the intricate structure of the developing cochlea.

Building on their earlier work on 301 cells, Kelleys team set out to examine the gene activity profiles of 30,000 cells from mouse cochleae collected at four time points, beginning with the 14th day of embryonic development and ending with the seventh postnatal day. Collectively, the data represents a vast catalog of information that researchers can use to explore cochlear development and to study the genes that underlie inherited forms of hearing impairment.

Kelleys team focused on one such gene, Tgfbr1, which has been linked to two conditions associated with hearing loss, Ehlers-Danlos syndrome and Loeys-Dietz syndrome. The data showed that Tgfbr1 is active in outer hair cell precursors as early as the 14th day of embryonic development, suggesting that the gene is important for initiating the formation of these cells.

To explore Tgfbr1s role, the researchers blocked the Tgfbr1 proteins activity in cochleae from 14.5-day-old mouse embryos. When they examined the cochleae five days later, they saw fewer outer hair cells compared to the embryonic mouse cochleae that had not been treated with the Tgfbr1 blocker. This finding suggests that hearing loss in people with Tgfbr1 mutations could stem from impaired outer hair cell formation during development.

The study revealed additional insights into the early stages of cochlear development. The developmental pathways of inner and outer hair cells diverge early on; researchers observed distinct gene activity patterns at the earliest time point in the study, the 14th day of embryonic development. This suggests that the precursors from which these cells derive are not as uniform as previously believed. Additional research on cells collected at earlier stages is needed to characterize the initial steps in the formation of hair cells.

In the future, scientists may be able to use the data to steer stem cells toward the hair cell lineage, helping to produce the specialized cells they need to test cell replacement approaches for reversing some forms of hearing loss. The studys results also represent a valuable resource for research on the hearing mechanism and how it goes awry in congenital forms of hearing loss.

The authors have made their data available through the gEAR portal(link is external) (gene Expression Analysis Resource), a web-based platform for sharing, visualizing, and analyzing large multiomic datasets. The portal is maintained by Ronna Hertzano, M.D., Ph.D., and her team in the Department of Otorhinolaryngology and the Institute for Genome Sciences (IGS)(link is external) at the University of Maryland School of Medicine.

Single-cell RNA sequencing data are highly complex and typically require significant skill to access, said Hertzano. By disseminating this study data via the gEAR, we are creating an encyclopedia of the genes expressed in the developing inner ear, transforming the knowledge base of our field and making this robust information open and understandable to biologists and other researchers.

This news release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process; each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge gained through basic research.

Reference: Kolla, L., Kelly, M. C., Mann, Z. F., Anaya-Rocha, A., Ellis, K., Lemons, A., Palermo, A. T., So, K. S., Mays, J. C., Orvis, J., Burns, J. C., Hertzano, R., Driver, E. C., & Kelley, M. W. (2020). Characterization of the development of the mouse cochlear epithelium at the single cell level. Nature Communications, 11(1), 116. https://doi.org/10.1038/s41467-020-16113-y

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Originally posted here:
30,000-cell Study Maps the Development of Sound Sensing in the Mouse Inner Ear - Technology Networks

The Stem Cell Therapy market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2026.

The report mainly studies the size, recent trends and development status of the Stem Cell Therapy market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Stem Cell Therapy market.

Download PDF Sample of Stem Cell Therapy Market report @ https://www.arcognizance.com/enquiry-sample/1030514

Major Players in the global Stem Cell Therapy market include:, Holostem Terapie Avanzate, Osiris Therapeutics, NuVasive, BIOTIME, Advanced Cell Technology, Caladrius, Pharmicell, JCR Pharmaceuticals, RTI Surgical, AlloSource, MEDIPOST, Anterogen, BrainStorm Cell Therapeutics

On the basis of types, the Stem Cell Therapy market is primarily split into:, Autologous, Allogeneic

On the basis of applications, the market covers:, Musculoskeletal disorders, Wounds and injuries, Cardiovascular diseases, Surgeries, Gastrointestinal diseases, Other applications

Brief about Stem Cell Therapy Market Report with [emailprotected] https://www.arcognizance.com/report/global-stem-cell-therapy-market-report-2019-competitive-landscape-trends-and-opportunities

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2014-2026) of the following regions:, United States, Europe (Germany, UK, France, Italy, Spain, Russia, Poland), China, Japan, India , Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam), Central and South America (Brazil, Mexico, Colombia), Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria), Other Regions

Chapter 1 provides an overview of Stem Cell Therapy market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of Stem Cell Therapy market by type, application, and region are also presented in this chapter.

Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.

Chapter 3 provides a full-scale analysis of major players in Stem Cell Therapy industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.

Chapter 4 gives a worldwide view of Stem Cell Therapy market. It includes production, market share revenue, price, and the growth rate by type.

Chapter 5 focuses on the application of Stem Cell Therapy, by analyzing the consumption and its growth rate of each application.

Chapter 6 is about production, consumption, export, and import of Stem Cell Therapy in each region.

Chapter 7 pays attention to the production, revenue, price and gross margin of Stem Cell Therapy in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.

Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.

Chapter 9 introduces the industrial chain of Stem Cell Therapy. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.

Chapter 10 provides clear insights into market dynamics.

Chapter 11 prospects the whole Stem Cell Therapy market, including the global production and revenue forecast, regional forecast. It also foresees the Stem Cell Therapy market by type and application.

Chapter 12 concludes the research findings and refines all the highlights of the study.

Chapter 13 introduces the research methodology and sources of research data for your understanding.

Years considered for this report:, Historical Years: 2014-2018, Base Year: 2019, Estimated Year: 2019, Forecast Period: 2019-2026,

Some Point of Table of Content:

Chapter One: Stem Cell Therapy Market Overview

Chapter Two: Global Stem Cell Therapy Market Landscape by Player

Chapter Three: Players Profiles

Chapter Four: Global Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

Chapter Five: Global Stem Cell Therapy Market Analysis by Application

Chapter Six: Global Stem Cell Therapy Production, Consumption, Export, Import by Region (2014-2019)

Chapter Seven: Global Stem Cell Therapy Production, Revenue (Value) by Region (2014-2019)

Chapter Eight: Stem Cell Therapy Manufacturing Analysis

Chapter Nine: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Stem Cell Therapy Market Forecast (2019-2026)

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Appendix continued

List of tablesList of Tables and FiguresFigure Stem Cell Therapy Product PictureTable Global Stem Cell Therapy Production and CAGR (%) Comparison by TypeTable Profile of AutologousTable Profile of AllogeneicTable Stem Cell Therapy Consumption (Sales) Comparison by Application (2014-2026)Table Profile of Musculoskeletal disordersTable Profile of Wounds and injuriesTable Profile of Cardiovascular diseasesTable Profile of SurgeriesTable Profile of Gastrointestinal diseasesTable Profile of Other applicationsFigure Global Stem Cell Therapy Market Size (Value) and CAGR (%) (2014-2026)Figure United States Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Europe Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Germany Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure UK Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure France Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Italy Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Spain Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Russia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Poland Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure China Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Japan Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure India Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Southeast Asia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Malaysia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Singapore Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Philippines Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Indonesia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Thailand Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Vietnam Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Central and South America Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Brazil Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Mexico Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Colombia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Middle East and Africa Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Saudi Arabia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure United Arab Emirates Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Turkey Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Egypt Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure South Africa Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Nigeria Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Global Stem Cell Therapy Production Status and Outlook (2014-2026)Table Global Stem Cell Therapy Production by Player (2014-2019)Table Global Stem Cell Therapy Production Share by Player (2014-2019)Figure Global Stem Cell Therapy Production Share by Player in 2018Table Stem Cell Therapy Revenue by Player (2014-2019)Table Stem Cell Therapy Revenue Market Share by Player (2014-2019)Table Stem Cell Therapy Price by Player (2014-2019)Table Stem Cell Therapy Manufacturing Base Distribution and Sales Area by PlayerTable Stem Cell Therapy Product Type by PlayerTable Mergers & Acquisitions, Expansion PlansTable Holostem Terapie Avanzate ProfileTable Holostem Terapie Avanzate Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Osiris Therapeutics ProfileTable Osiris Therapeutics Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table NuVasive ProfileTable NuVasive Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table BIOTIME ProfileTable BIOTIME Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Advanced Cell Technology ProfileTable Advanced Cell Technology Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Caladrius ProfileTable Caladrius Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Pharmicell ProfileTable Pharmicell Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table JCR Pharmaceuticals ProfileTable JCR Pharmaceuticals Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table RTI Surgical ProfileTable RTI Surgical Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table AlloSource ProfileTable AlloSource Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table MEDIPOST ProfileTable MEDIPOST Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Anterogen ProfileTable Anterogen Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table BrainStorm Cell Therapeutics ProfileTable BrainStorm Cell Therapeutics Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Global Stem Cell Therapy Production by Type (2014-2019)Table Global Stem Cell Therapy Production Market Share by Type (2014-2019)Figure Global Stem Cell Therapy Production Market Share by Type in 2018Table Global Stem Cell Therapy Revenue by Type (2014-2019)Table Global Stem Cell Therapy Revenue Market Share by Type (2014-2019)Figure Global Stem Cell Therapy Revenue Market Share by Type in 2018Table Stem Cell Therapy Price by Type (2014-2019)Figure Global Stem Cell Therapy Production Growth Rate of Autologous (2014-2019)Figure Global Stem Cell Therapy Production Growth Rate of Allogeneic (2014-2019)Table Global Stem Cell Therapy Consumption by Application (2014-2019)Table Global Stem Cell Therapy Consumption Market Share by Application (2014-2019)Table Global Stem Cell Therapy Consumption of Musculoskeletal disorders (2014-2019)Table Global Stem Cell Therapy Consumption of Wounds and injuries (2014-2019)Table Global Stem Cell Therapy Consumption of Cardiovascular diseases (2014-2019)Table Global Stem Cell Therapy Consumption of Surgeries (2014-2019)Table Global Stem Cell Therapy Consumption of Gastrointestinal diseases (2014-2019)Table Global Stem Cell Therapy Consumption of Other applications (2014-2019)Table Global Stem Cell Therapy Consumption by Region (2014-2019)Table Global Stem Cell Therapy Consumption Market Share by Region (2014-2019)Table United States Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Europe Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table China Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Japan Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table India Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Southeast Asia Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Central and South America Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)continued

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

See the original post here:
Global Stem Cell Therapy Market 2020 Research Report Insights and Analysis, Forecast to 2026 - 3rd Watch News

Mesenchymal Stem Cells Market Trends by Manufacturers, States, Type and Application, Forecast to 2019 2027

Global Mesenchymal Stem Cells Market: Snapshot

The increasing use of mesenchymal stem cells (MSCs) for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market. Mesenchymal stem cells are adult stem cells that are of various types such as adipocytes, osteocytes, monocytes, and chondrocytes.

The main function of mesenchymal stem cells is to replace or repair damaged tissue.

Report Overview @www.transparencymarketresearch.com/mesencharket.html

Mesenchymal stem cells are multipotent, i.e. they can produce more than one type of specialized cells.

These specialized cells have their own distinguishing shapes, structures, and functions, with each of them belonging to a particular tissue.

Mesenchymal stem cells are traditionally found in the bone marrow. However, these cells can also be separated from other tissues such as cord blood, fallopian tube, peripheral blood, and fetal liver and lung.

Mesenchymal stem cells have long thin cell bodies containing a large nucleus. MSCs have enormous capacity for renewal keeping multipotency.

Due to these virtues, mesenchymal stem cells have huge therapeutic capacity for tissue repair.

Get Brochure of the Report @www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells can differentiate into a number of cell types that belong to our skeletal tissues that include cartilage, bone, and fat. Research is underway to discover if mesenchymal stem cells can be used to treat bone and cartilage diseases.

Scientists are also exploring the possibility if mesenchymal stem cells differentiate into other type of cells apart from skeletal tissues. This includes nerve cells, liver cells, heart muscle cells, and endothelial cells.

This will lead to mesenchymal stem cells to be used to treat other diseases.

Stem cells are specialized cells which have the capability of renewing themselves through cell division and differentiate into multi-lineage cells. Mesenchymal stem cells (MSCs) are non- hematopoietic, multipotent adult stem cells which can be isolated from bone marrow, cord blood, fat tissue, peripheral blood, fallopian tube, and fetal liver and lung tissue.

Request For Covid19 Impact Analysis http://www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells have the capacity to differentiate into mesodermal lineages, such as chondrocytes, adipocytes, and osteocytes, and non-mesodermal lineages such as ectodermal (neurocytes) and endodermal lineages (hepatocytes). These stem cells have specific features such as multilineage potential, secretion of anti-inflammatory molecules, and immunomodulation.

These cells have emerged as promising therapeutic agents for regenerating skeletal tissues such as damaged bone and cartilage tissues and treatment of chronic diseases owing to their specific features.

The global mesenchymal stem cells market is expected to be driven by the increasing clinical application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases. Studies have shown that these stem cells enhance the angiogenesis in myocardium and allow the reduction of myocardial fibrotic area.

The pre-clinical studies for using mesenchymal stem cells in treatment of cardiovascular diseases, liver diseases, and cancer are projected to create new market opportunities for mesenchymal stem cells. Mesenchymal stem cells also produce anti-inflammatory molecules which modulate humoral and cellular immune responses.

Features of these stem cells such as ease of isolation, regenerative potential, and immunoregulatory, the mesenchymal stem cell therapy has emerged as a promising tool for the treatment of chronic diseases, degenerative, inflammatory, and autoimmune diseases.

Pre Book Now @www.transparencymarketresearch.com/checkoump;ltype=S

Clinical studies are exploring MSCs for various conditions such as orthopedic injuries, graft versus host disease following bone marrow transplantation, and genetic modification of MSCs to overexpress antitumor genes for use as anticancer therapy, which are exhibiting new opportunities in therapeutic area. However, the mesenchymal stem cell research studies are tedious, lengthy, and complex.

In some cases, due to some adverse effects transplanted mesenchymal stem cells rapidly removed from the body which limits use of stem cells in therapeutic treatments. The conflicting results and regulatory compliances for approvals may also hamper the growth of this market.

The global mesenchymal stem cells market is segmented on the basis of source of isolation, end-user, and region. Stem cells are isolated from the bone marrow, peripheral blood, lung tissue, umbilical cord blood, amniotic fluids, adipose tissues, and synovial tissues.

Traditionally the MSCs were isolated from bone marrow aspiration which is associated with risk of infection and painful for the patient. The MSCs from adipose tissues are usually isolated from the biological material generated during liposuction, lipectomy procedures by using collagenase enzymatic digestion followed by centrifugation and washing.

In terms of end-user, the market is segmented into clinical research organizations, biotechnological companies, medical research institutes, and hospitals.

Read our Case study at :www.transparencymarketresearch.com/casestug-start-up

Geographically, the global mesenchymal stent cells market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to continue its dominance in terms of market share during the forecast period owing to high R&D expenditure, availability of advanced research facilities and skilled professionals, and government initiatives.

Europe is the second largest market after North America. The Asia Pacific market is projected to expand at a high CAGR during the forecast period due to increased R&D budgets in Japan, China, and India.

Key global players operating in the mesenchymal stem cells market include R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience Ltd., Cyagen Biosciences Inc., Cytori Therapeutics Inc., Stemcelltechnologies Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read the original:
Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News

ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc.. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Imstem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeXs embryonic stem cell line ESI 053 to derive ImStems investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes. AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement.

ImStem has previously used AgeX ESI 053 to derive the ImStem IMS001 product which is being investigated for multiple sclerosis under an IND. Earlier this year, the U.S. Food and Drug Administration (FDA) cleared IMS001 to begin a Phase 1 clinical study in patients with multiple sclerosis, after a clinical hold on its Investigational New Drug (IND) application was removed. This is believed to be the first MSC product derived from human embryonic stem cells to be accepted for a clinical trial by the FDA. AgeX and ImStem already have a commercial license in place, which grants ImStem rights to use AgeXs ESI 053 to derive IMS001 as a product candidate for development in autoimmune disease, including multiple sclerosis.

To date, in patients with pneumonia and ARDS due to COVID-19, preliminary literature suggests MSCs, such as ImStems hES-MSC candidate IMS001, may warrant further development consideration. An early clinical study conducted in China by an unrelated group with a different MSC product, Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia, and published in Aging and Disease (2020, Vol. 11, No. 2, pp. 216-228) showed that an intravenous infusion of a different MSC product appeared safe and improved functional outcomes in seven treated patients with COVID-19 pneumonia. MSCs are well recognized to be immunomodulatory in nature, possessing immunosuppressive and anti-inflammatory properties.

Even before their application to COVID-19, MSCs were being investigated as a potential therapeutic option in ARDS, and emerging data in preclinical models has been encouraging. ARDS remains an area of considerable unmet medical need, affecting around 200,000 patients annually in the U.S., accounting for 10% of all intensive care unit patients, and having a mortality of approximately 40%. At the present time, no specific direct therapies exist for ARDS and only supportive treatment is available.

We feel privileged to be part of a global effort to combat COVID-19. This is a unique opportunity for AgeX to leverage its resources to help with the public health challenge at hand. Decades of pioneering work with human embryonic stem cells means this technology is now at a point where it may play a role in the development of a cell-based approach to combating COVID-19. We are very excited by the prospect of expanding our relationship with ImStem to include COVID-19 and ARDS, said Dr. Nafees Malik, Chief Operating Officer of AgeX.

We welcome the opportunity to continue to collaborate with AgeX and explore future development of our IMS001 product in COVID-19 and ARDS from other causes, commented Richard Kim, M.D., Chief Medical Officer of ImStem Biotechnology.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. AgeXs PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The company's mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology Inc. is a privately held company headquartered in Farmington, CT.

For more information, visit http://www.imstem.com.

Forward-Looking Statements for AgeX

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs letter of intent with ImStem there is no assurance that (i) AgeX and ImStem will successfully conclude negotiations and enter into a license agreement; (ii) ImStem will be successful in developing any therapeutic products from a stem cell line licensed by AgeX or that any therapeutic product that may be developed will receive FDA or foreign regulatory approval, or (iii) AgeX will derive revenue or other financial benefits from any license agreement that might be signed with ImStem. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005353/en/

See the rest here:
AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other...

MedicalResearch.com Interview with:

Charles-de-SM.D., Ph.D.Rio de Janeiro, Brazil

MedicalResearch.com: What is the background for this study?

Response: Our clinical trial was based on our clinical skin observations in areas submitted to a lipotransfer previously, an ordinary practice in plastic surgery. These clinical observations lead us to investigate what will be the key element played in these findings. Our scientific support investigation addressed the Dardick1and Zuk, P2 studies, that demonstrated fibroblastic-like cells in adipose tissue with regenerative ability. Our clinical trial proposal is to investigate the adipose-derived stem cell (ADSC) role in the photoaged skin. The direct endpoint of the study was to assess the histological benefits provided by the subdermal ADSC injection. Mesenchymal stem cells were obtained from lipoaspirates, expanded in vitro, and introduced into the facial skin of 20 patients submitted after three to four months to a face-lifting surgery. In the retrieved skin, immunocytochemical and ultrastructural analysis quantified elastic matrix components, cathepsin-K, metalloprotease MMP-12, and the macrophage M2 markers: CD68, CD206 and heme-oxygenase-1.An overview of the trial steps is described in the infographic.

MedicalResearch.com: What are the main findings?

Response:A full de novo formation of oxytalan and elaunin fibers was observed in the subepidermal region, with a reconstitution of the papillary structure of the dermal-epidermal junction. Elastotic deposits in the deep dermis were substituted by a normal elastin fiber network. The coordinated removal of the pathologic deposits of old elastic fibers and their substitution by the normal ones was concomitant with activation of cathepsin-K and MPP12, and with expansion of the M2 macrophage infiltration.

MedicalResearch.com: What should readers take away from your report?

Response: This study has demonstrated ADSC to remodeling the skin extra cellular matrix, mainly in the elastic system.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Based on these findings, the future of thisresearch line aims to create new possibilities in regenerative cell therapy not only in skin diseases, but also in other clinical applicability in the case of organs and tissues with reduction and / or alteration in the elastic system (ex: aneurysms, cardiac valve disease and others), with a better understanding of the mechanisms involved and the control of these processes.

MedicalResearch.com: Is there anything else you would like to add? Any disclosures?

Response: It is interesting to be able, in future studies, to evaluate other mechanisms involved and the duration of effects regenerative effects on skin treated with ADSC. Another question could be considered: optimized ADSC (quantity) / area with the tissue effect found. We have not any to disclosure. This study was developed by federal university of Rio de Janeiro-Brasil and Verona University-Italy

Citation:

Charles-de-S, Luiz M.D., Ph.D.; Gontijo-de-Amorim, Natale Ferreira M.D., Ph.D.; Rigotti, Gino M.D., Ph.D.; Sbarbati, Andrea M.D., Ph.D.; Bernardi, Paolo Ph.D.; Benati, Donatella Ph.D.; Bizon Vieira Carias, Rosana Ph.D.; Maeda Takiya, Christina M.D., Ph.D.; Borojevic, Radovan Ph.D. Photoaged Skin Therapy with Adipose-Derived Stem Cells, Plastic and Reconstructive Surgery: June 2020 Volume 145 Issue 6 p 1037e-1049e doi: 10.1097/PRS.0000000000006867

References:

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

0

Go here to read the rest:
Photoaged Skin Therapy with Adipose-Derived Stem Cells - MedicalResearch.com

Stem Cell Antibody Market Research Report released by Research N Reports is a tool to inform businesses on histories, current trends and ample research to navigate through its complexities. Effective business strategies of the leading key players and startups have been explained in detail. The Stem Cell Antibody Market is expected to reach at a huge CAGR during the forecast period.

The research report details the classification of the Stem Cell Antibody Market. The Stem Cell Antibody Market is divided into several segments based on materials, types, applications, and end-users. The report also includes a geographic analysis of the global market. The vital information mentioned in the research report will help to predict the future of the global market.

For Sample Copy of this report: https://www.researchnreports.com/request_sample.php?id=790931

The report delivers a comprehensive overview of the crucial elements of the Market and elements such as drivers, restraints, current trends of the past and present times, supervisory scenario, and technological growth. A thorough analysis of these elements has been accepted for defining the future growth prospects of the global Stem Cell Antibody Market.

Key Players:

Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.)

This statistical surveying research report on the Stem Cell Antibody is an all-inclusive study of the business sectors latest outlines, industry growth drivers, and inadequacies. It gives market forecasts for the coming years. It contains an examination of the latest progressions in technology, Porters five force analysis and dynamic profiles of exclusive industry competitors. The report besides conveys an investigation of trivial and full-scale factors prosecuting for the new candidates in the market and the ones currently in the market.

Ask for Discount on this Report: https://www.researchnreports.com/ask_for_discount.php?id=790931

Reasons for Buying this Report:

Across the globe, several regions like North America, Latin America, Asia-Pacific, Europe, and Africa have been studied on the basis of sale and profit margin. Some significant key players have been profiled to get informative data to make informed decisions in the businesses. It makes use of info graphics, graphs, charts, tables, and pictures. For an effective and accurate business outlook, the report on the global Stem Cell Antibody Market examined details of the changing trends adopted by the top level companies.

Get Complete [emailprotected] https://www.researchnreports.com/enquiry_before_buying.php?id=790931

About Us:

Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a sound board firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on current market conditions or being ahead in the cut throat Global competition. Since we excel at business research to help businesses grow, we also offer consulting as an extended arm to our services which only helps us gain more insight into current trends and problems. Consequently we keep evolving as an all-rounder provider of viable information under one roof.

Contact:

Sunny Denis

Research N Reports

10916, Gold Point Dr,

Houston, TX, Pin 77064,

+1 510-402-1213,

[emailprotected]

https://www.researchnreports.com

See the rest here:
Global Stem Cell Antibody Market Insights 2020 Demand Growing Rapidly with Major Player- Thermo Fisher Scientific, Merck Group, Abcam plc - Cole of...

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Stem Cell Antibody Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Stem Cell Antibody market. We have also provided absolute dollar opportunity and other types of market analysis on the global Stem Cell Antibody market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Stem Cell Antibody market. All findings and data on the global Stem Cell Antibody market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Stem Cell Antibody market available in different regions and countries.

The report on the Stem Cell Antibody market provides a birds eye view of the current proceeding within the Stem Cell Antibody market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Stem Cell Antibody market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2548440&source=atm

The authors of the report have segmented the global Stem Cell Antibody market as per product, application, and region. Segments of the global Stem Cell Antibody market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Stem Cell Antibody market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

The following manufacturers are covered:Thermo Fisher Scientific, Inc. (U.S.)Merck Group (Germany), Abcam plc (U.K.)Becton, Dickinson and Company (U.S.)Bio-Rad Laboratories, Inc. (U.S.)Cell Signaling Technology, Inc. (U.S.)Agilent Technologies, Inc. (U.S.)F. Hoffmann-La Roche Ltd (Switzerland)Danaher Corporation (U.S.)GenScript (U.S.), PerkinElmer, Inc. (U.S.)Lonza (Switzerland), and BioLegend, Inc. (U.S.)

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypePrimary AntibodiesSecondary Antibodies

Segment by ApplicationProteomicsDrug DevelopmentGenomics

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2548440&source=atm

Stem Cell Antibody Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Stem Cell Antibody Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Stem Cell Antibody Market in South, America region is also expected to grow in near future.

The Stem Cell Antibody Market report highlights is as follows:

This Stem Cell Antibody market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Stem Cell Antibody Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Stem Cell Antibody Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Stem Cell Antibody Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2548440&licType=S&source=atm

Read more:
Potential impact of coronavirus outbreak on Stem Cell Antibody Market: Opportunities and Forecast Assessment, 2019-2025 - 3rd Watch News

Recently MarketsandResearch.biz has published a new report entitled Global Cell Isolation Technology Market Growth (Status and Outlook) 2020-2025 goes into the past for analyzing the market scenario, at the same time, it provides a complete insight into the market. Starting from the number of sales made, the price structure of each segment, revenue generated and expected to be made, the margin of the profit, past performance, and all other aspects that can influence the market are covered in this report. The report has segmented and sub-segmented with respect to regions, players, dynamics, and strategies to simplify the actual conditions of the industry. It development trends, competitive landscape analysis, and key regions development status on the types, applications, and major players of the global Cell Isolation Technology market are studied in detail.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/59723

The Advancements Are Investigated Widely To Understand The Probable Impact On The Growth of The Global Market:

The Cell Isolation Technology market has been segmented into key segments such as product types, end-users, leading regions, and noteworthy players. The market report also includes statistics about sales, consumption rate, volume, value, gross margin, and more. The report also inspects the financial standing of the leading companies, which covers gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios. The segmentation included in the report is beneficial for companies to reach desired business goals. Business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions are some of the business events made by key players.

Leading manufacturers/companies operating at both regional and global levels: Thermo Fisher Scientific, Inc., Merck, Beckman Coulter, Inc., Terumo BCT, BD Biosciences, Bio-Rad Laboratories, Inc., GE Healthcare, Stemcell Technologies,

With the product, the market could be divided into: Centrifugation, Flow Cytometry, Cell Electrophoresis,

With users/application, the market can be split into: Stem cell research, Cancer research, Tissue regeneration, In-vitro diagnostics, Other

By Leading Regions:

Analysts have created this report by gathering information through primary through surveys and interviews and secondary included industry body databases, reputable paid sources, and trade journal methods of data collection. The report includes exhaustive qualitative and quantitative evaluation. Analysts have taken meticulous efforts to take a look at the right and valuable statistics and serve this intelligence document.

This includes key regional areas such as Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/59723/global-cell-isolation-technology-market-growth-status-and-outlook-2020-2025

Why Should One Grab This Industry Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Link:
Global Cell Isolation Technology Market 2020 SWOT Analysis & Key Business Strategies by Leading Industry Players and Forecast 2025 - 3rd Watch...

With an aim to be a part of top 500 universities of the world, Banaras Hindu University (BHU) is expanding its international hostel, building smart classrooms, upgrading graduate and postgraduate laboratories, and beautifying its campus under the institute of excellence (IoE) scheme, said BHU public relations officer Dr Rajesh Singh.

Giving details of achievements of BHU in last one year, Dr Singh said that the government had sanctioned Rs 1000 crore under IoE scheme a few months ago to the university for upgrading infrastructure, academic and research facilities, laboratories, central and departmental libraries within five years.

Work has already started for upgrading academic and research facilities. The international hostel of 110 rooms is almost ready. It will help the university attract more foreign students.

He said with the financial support of the ministry of human resource development and union ministry of health and family welfare, a super speciality block worth Rs 200 crore has been built in BHU.

After being inaugurated by Prime Minister Narendra Modi, it is already functional. At present, it is providing medical services to Covid-19 patients. It is equipped with operation theatres, and biochemistry lab and pathology.

Moreover, bone marrow transplant and stem cell research centre have also been set up, construction of regional eye centre with an estimated cost of Rs 38.5 crore is about to be completed.

Singh said that with the financial support of union human resource development ministry, a central discovery centre, equipped with state of the art facilities, for research in basic and practical science is also being set up.

A SATHI centre with an estimated cost of Rs 125 crore is being set up in BHU. Under one roof, there will be facilities for innovation, entrepreneurship and development of startups.

He said that a centre for Vedic science has been set up in the university for research and to establish a link between ancient Indian knowledge and modern science. The centre will also work for reestablishing the excellent sources of knowledge, Vedas and its wide area and will also study their effect in understanding modern science and technology.

BHU has also signed an MoU with solar energy corporation for setting up a solar energy centre and a green energy centre for study in this field.

Dr Singh said that 369 research projects worth over Rs 157 crore are underway in the university.

Follow this link:
BHU prepares to be amongst top 500 global universities - Hindustan Times